Frequency Therapeutics Inc Aktie News

Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript

Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

- Program to feature presentations from the company management about  KRRO-121 for the potential treatment of hyperammonemia , a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing perspectives on living with urea cycle disorder - CAMBRIDGE, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that the company will host...

CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 10:30 a.m. PT (1:30 p.m. ET). Todd Chappell, Chief Operating Officer, and Loic Vincent, Ph.D., Chief Scientific Officer, will al...

Korro Bio stock plummeted Thursday after its RNA-editing drug failed to pass muster in patients with a rare lung and liver disease.

Korro is the latest to rethink its ties with the Danish pharma company.

CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- — KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients     — KRRO-110 did not reach projected levels of functional protein following a single administration      — Pivoting to GalNAc delivery for patients with AATD; development candidate nomination expected in the first half of 2026     — Nominated KRRO-121, d...

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of September: